| Methods |
Randomised controlled trial, double‐blind |
| Participants |
Patients with neutropenia < 500/mm3 or < 1000 and decreasing. Fever ≥ 38
Mean age 48.2 yrs with any type of cancer |
| Interventions |
Teicoplanin 400 mg x 1 versus placebo for persistent fever at 72‐96 hrs
Non‐intervention antibiotics: imipenem |
| Outcomes |
Failure
Mortality (all‐cause and infection‐related)
Superinfections |
| Notes |
First modification design
Single centre, the Netherlands |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Low risk |
Computer‐assisted randomisation |
| Allocation concealment (selection bias) |
Low risk |
Randomisation performed by the hospital pharmacy |
| Blinding of participants and personnel (performance bias)
All outcomes |
Low risk |
|
| Blinding of outcome assessment (detection bias)
All outcomes |
Low risk |
|
| Incomplete outcome data (attrition bias)
All outcomes |
High risk |
|
| Other bias |
High risk |
Patients included for different episodes and analysis by episode |
